Biomolecular contrast agents for therapy optimization in radiation therapy with proton or ion beams
First Claim
Patent Images
1. A method for treating a target with a beam of energy, said target being within a biological organism, said method comprising:
- introducing a bio-molecular contrast agent (BMCA) into said biological organism, said BMCA being capable of at least one of binding to said target and reacting with said target, said BMCA capable of also giving detectable signals;
irradiating said target using said beam of energy in accordance with a pre-therapy plan;
after said BMCA has bound or reacted to said target, determining if said BMCA signals indicate that the conditions of said target have varied from said pre-therapy plan;
if deemed necessary optimizing said irradiating of said target in accordance with varied conditions.
1 Assignment
0 Petitions
Accused Products
Abstract
Bio-molecular contrast agents (BMCA) can be used for optimizing radiation dosage, energy and/ or duration in order to achieve on-line, real-time therapy optimization. The BMCA signals during treatment are compared with expected values to determine what, if any, therapy optimization is needed.
34 Citations
23 Claims
-
1. A method for treating a target with a beam of energy, said target being within a biological organism, said method comprising:
-
introducing a bio-molecular contrast agent (BMCA) into said biological organism, said BMCA being capable of at least one of binding to said target and reacting with said target, said BMCA capable of also giving detectable signals;
irradiating said target using said beam of energy in accordance with a pre-therapy plan;
after said BMCA has bound or reacted to said target, determining if said BMCA signals indicate that the conditions of said target have varied from said pre-therapy plan;
if deemed necessary optimizing said irradiating of said target in accordance with varied conditions. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A system for treating a target with a beam of energy from a therapy device, said target within a biological organism, said therapy device initially configured for treating according to a pre-therapy plan, said system comprising:
-
a sensing system configured to detect signals from bio-molecular contrast agents (BMCA) introduced into said biological organism, said BMCA binding to or reacting with said target;
a decision system configured to compare said sensed BMCA signals with expected BMCA signals and determine any variance in conditions from said pre-therapy plan therefrom; and
a therapy device control system configured to optimize the treating of said target based upon said any variance. - View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22, 23)
-
Specification